Trial Profile
Reversing Type 1 Diabetes After it is Established: A Pilot Safety and Feasibility Study of Anti-Thymocyte Globulin (Thymoglobulin)and Pegylated GCSF (Neulasta) in Established Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Pegfilgrastim (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- 16 Jul 2019 Status changed from active, no longer recruiting to completed.
- 19 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 07 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Sep 2018.